Former Global Chief Scientific and Chief Medical Officer · VERACYTE, INC. (VCYT)

Giulia Kennedy

A named executive officer of VERACYTE in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,533,563

Salary $500,000Stock awards $1,953,926

FY2021: $2,636,699

3rd of 5 named executive officers at Veracyte by FY2022 total.

5 named officers on file for VERACYTE, FY2022

Giulia Kennedy’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 8 equity grants, each cited to its filing
  • VCYT’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how VERACYTE’s whole pay program stands against its peers

  • VERACYTE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VCYT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2023 (DEF 14A).

Free

Get Giulia Kennedy’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Giulia Kennedy compensation by year

VERACYTE Summary Compensation Table · all 4 fiscal years held
In US dollars, as VERACYTE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$421,000$451,000$469,050$500,000
Bonus$33,107$1,950$0$0
Stock awards$808,400$304,245$1,225,763$1,953,926
Option awards$638,310$863,315$719,605$1,408,639
Non-equity incentive$221,593$248,050$219,281$0
Pension and deferred compensation$0$0$0$0
All other$2,000$2,000$3,000$670,998
Total$2,124,410$1,870,560$2,636,699$4,533,563

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: VERACYTE, INC. DEF 14A filed April 27, 2023, accession 0001384101-23-000055, and prior-year filings. Open the filing on EDGAR.

How this page was built: the VERACYTE, INC. filed document, accession 0001384101-23-000055. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.

$2.1M
$1.9M
$2.6M
$4.5M
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

VERACYTE’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Marc StapleyChief Executive Officer$4,935,422
Tina NovaGeneral Manager, Decipher Urologic Cancers$4,598,529
Giulia Kennedy · this pageFormer Global Chief Scientific and Chief Medical Officer$4,533,563
Rebecca ChambersChief Financial Officer$3,322,756
Annie McGuireGeneral Counsel and Chief People Officer$2,447,055

The full VERACYTE compensation record

free company brief

This page is one person within VERACYTE's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are VERACYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Giulia Kennedy's compensation dossier · One-time report. No refunds.